Peter Feinberg’s Post

Can a patient’s genomic profile indicate a mixed tumor? Dr. Jason Porter discusses how he has found the presence of TP53 and RB1 to be likely indicators of a mixed tumor in patients with confirmed adenocarcinomas. This is the 1st in a 4 part series featuring leading experts in thoracic oncology on topics such as advancements in care, treatment options, costs and treatment challenges. The series entitled PRIMO Interdisciplinary Challenges in SCLC Management was made possible by a sponsorship from G1 Therapeutics and published by our sister company, PRIMO. https://lnkd.in/eAfuvBrf #ThoracicOncology #GenomicProfile #TP53 #SCLC

(7/9) About 28,000 people in the U.S. are diagnosed each year with NRAS-mutant solid tumors, including #melanoma, #NSCLC and #CRC. Existing treatments either target all RAS proteins (pan-RAS), or target other downstream parts of the pathway, which leads to significant off-target toxicity and limits efficacy. We have created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS. We expect to initiate clinical development of this inhibitor in the second half of 2025.

#ICYMI Ratio recently dosed the first patient in a new Phase I study, in collaboration with Lantheus and PharmaLogic, for our FAP-targeted radiopharmaceutical for PET imaging, RTX-1363S. FAP is a protein expressed in nearly all epithelial-derived cancers that makes it unique target for tumor imaging in a wide variety of cancers, including breast, pancreatic, lung, and stomach cancers. Learn more: https://lnkd.in/ezdJhEtF

It is well-established that syngeneic tumour models are a powerful tool to evaluate novel therapies targeting the immune system. However, the key to understanding your immuno-modulatory compound’s efficacy is to work with well-characterised models, with known growth kinetics and response to standard of care treatments (SOC). View our data from our colorectal carcinoma (MC38 cell line) model containing growth curve (tumour growth control vs in response to PD-1 treatment), example of bioluminesence imaging of orthotopically implanted tumour (MC38-luc cell line) and a fully validated myeloid and lymphocyte cell panels here: https://lnkd.in/esn5FEwA #OncologyCROServices #EuropeanCRO #OncologyResearchSolutions #PreclinicalResearch

Oncology helps to understand retinal neovascolarisation:It is amazing how many similarities exist between the concepts of tumour neovascolarisation discovered by oncologists and retinal neovascolarisation: this not-to-be-missed lecture makes it possible to use their knowledge to better understand (and treat?) wet macular degeneration. https://lnkd.in/dnPjsBbe

Binging your favorite Halloween movies makes it harder than normal to keep up with exciting new clinical trial results. That's why we started the “Clinical trials to watch” blog series, highlighting Phase 1–3 trials and how #singlecell and #spatialbiology tools have supported clinical findings. Read the first post in the series with this study of an antibody therapy that was able to reduce metastatic tumor bulk and EMT score in stage IV endometrial carcinoma.

Bispecific T cell engagers (TCEs) have shown efficacy in hematological cancers, yet addressing solid tumors remains challenging due to limited T cell infiltration and anergy. Our next-generation trispecific T cell engager platform, with integrated costimulation (TriTCE Co-Stim) aims to enhance T cell activity by providing optimized CD3 and CD28 signaling, which may translate to improved patient responses in the treatment of solid tumors. https://lnkd.in/e_MABiPz #AACR24 Lisa Newhook Purva Bhojane

As precision oncology data continues to evolve, there is a greater need for molecular tumor board meetings in order to optimize patient treatment selection. However, the process for running these meetings is both time-consuming and costly to complete. The GenomOncology (GO) Molecular Tumor Board solution is designed to automate Tumor Board processes, reducing the time and costs associated with running molecular tumor board meetings. Learn more about how GenomOncology’s solution can streamline patient treatment recommendations, giving patients quicker insight into treatment opportunities. https://ow.ly/azCq50Qc97H #precisiononcology #moleculartumorboard

The Poor Richard’s Almanac proverb, “time lost is never found again,” applies to head and neck cancer since treatment delays or discontinuations from severe oral mucositis are a risk factor for recurrence and shortened survival times. The Phase 2 clinical trial, KEVLARx will combine RRx-001 (nibrozetone) with cisplatin and radiotherapy to prevent or mitigate the toxicity of severe oral mucositis. Read more here: https://bit.ly/4dd8nlv.

In a pre-specified interim analysis of the Phase 2 KEYNOTE-B84 study evaluating pepinemab in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for immunotherapy of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), pepinemab induced lymphoid structures were associated with an approximate doubling of objective responses (ORR) and progression free survival (PFS) relative to historical results with checkpoint monotherapy in patients with hard-to-treat tumors that express low levels of PD-L1 (CPS<20). https://bit.ly/47fm7Z9 #SITC23 #SITC2023 #Bcells